Literature DB >> 30128482

Missing Conflict of Interest Disclosure.

.   

Abstract

Year:  2018        PMID: 30128482      PMCID: PMC8177234          DOI: 10.1001/jamaoncol.2018.4091

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  8 in total

1.  Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.

Authors:  Bishal Gyawali; Vinay Prasad
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

2.  Inconsistent Reporting of Potential Conflicts of Interest.

Authors:  Vinay Prasad
Journal:  JAMA Oncol       Date:  2018-10-01       Impact factor: 31.777

3.  Is "Do Everything!" Always Appropriate?-Reply.

Authors:  Tomasz M Beer; Vinay Prasad
Journal:  JAMA Oncol       Date:  2017-11-01       Impact factor: 31.777

4.  Overall Survival vs Disease-Specific Survival-Reply.

Authors:  Sham Mailankody; Vinay Prasad
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

5.  Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.

Authors:  Vinay Prasad; Victoria Kaestner; Sham Mailankody
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

6.  Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.

Authors:  Inmaculada Hernandez; Vinay Prasad; Walid F Gellad
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

7.  Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

Authors:  John Marquart; Emerson Y Chen; Vinay Prasad
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

8.  Overestimating the Benefit of Cancer Drugs.

Authors:  Vinay Prasad
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.